
An analysis from the global database Biotechgate shows that Danish biotech companies are markedly smaller than in the countries we are usually compared to. This week the Medwatch Panel considers if the small size of the companies is a problem for the industry and what could be done about it.
Is it a problem for Denmark that we have all these small companies, and who – if any – can change that reality?
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app